Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of the Effects of Different Interventions on Glycemic Control in Newly-Diagnosed Type 2 Diabetic Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. informed consents be given before treatment~2. the newly-diagnosed type 2 diabetic patients~3. fasting blood glucose (FBG) level ranging from 7.0～16.7 mmol/L~4. age ranging from 25～70 years old~5. body mass index (BMI) ranging from20～35kg/m2~6. never be treated with any anti-hyperglycemic agents or anti-hyperlipidemic agents~Exclusion Criteria:~1. having any severe acute or chronic complications~2. renal dysfunction, blood creatinine≥150µmol/L~3. blood aminotransferase level rising up(more than 2 times of the normal level)~4. any severe cardiac disease including congestive cardiac failure, unstable angina and myocardial infarct in 12 months~5. serious hypertension (systolic pressure≥180mmHg and/ or diastolic pressure≥110mmHg)~6. chronic or acute pancreatic disease~7. severe systematic diseases or malignant tumor~8. allergic to the drugs using in the trial~9. any factors interfering the result~10. female patients incline to be pregnant~11. being treated with corticosteroid, immunosuppressing drugs or cytotoxic drugs~12. poor compliance

- Gender: ALL
- Minimum Age: 25 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- CSII (Type: ACTIVE_COMPARATOR): Patients in continuous subcutaneous insulin infusion group received Human Insulin (Novolin-R, Novo Nordisk) with an insulin pump (H-Tron Plus V100; Disetronic Medical System, Burgdorf, Switzerland);
- MDI (Type: ACTIVE_COMPARATOR): Patients in MDI group were treated with pre-meal Novolin-R, and Human Insulin NPH (Novolin-N, Novo Nordisk) at bedtime. Initial insulin doses were 0.4-0.5 IU/kg and total daily doses were divided into 50% of basal and 50% of bolus injection in CSII group and 30%-20%-20%-30% in multiple daily insulin injection group
- OHA (Type: ACTIVE_COMPARATOR): In oral hpoglycemic agents group, the patients with 20 kg/m2\<BMI≤25kg/m2 were initiated with Gliclazide (Diamicron, Servier) 80mg Bid (maximum to 160mg Bid), the patients with 25kg/m2\<BMI≤35kg/m2 were initiated with Metformin (Glucophage, BMS) 0.5 Bid (maximum to 2.0g/d), the combination of Diamicron and Glucophage was used in patients who could not achieve glycaemic control goal with one OHA or with FPG≥11.1mmol/l at randomization

Based on this trial design, predict the completion outcome and termination type (if applicable).